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Abstract
Background: Recent studies have suggested that the scavenger receptor MARCO (macrophage receptor with
collagenous structure) mediates activation of the immune response in bacterial infection of the central nervous
system (CNS). The chemotactic G-protein-coupled receptor (GPCR) formyl-peptide-receptor like-1 (FPRL1) plays an
essential role in the inflammatory responses of host defence mechanisms and neurodegenerative disorders such as
Alzheimer’s disease (AD). Expression of the antimicrobial peptide cathelicidin CRAMP/LL-37 is up-regulated in
bacterial meningitis, but the mechanisms underlying CRAMP expression are far from clear.
Methods: Using a rat meningitis model, we investigated the influence of MARCO and FPRL1 on rCRAMP (rat
cathelin-related antimicrobial peptide) expression after infection with bacterial supernatants of Streptococcus
pneumoniae (SP) and Neisseria meningitides (NM). Expression of FPRL1 and MARCO was analyzed by
immunofluorescence and real-time RT-PCR in a rat meningitis model. Furthermore, we examined the receptor
involvement by real-time RT-PCR, extracellular-signal regulated kinases 1/2 (ERK1/2) phosphorylation and cAMP
level measurement in glial cells (astrocytes and microglia) and transfected HEK293 cells using receptor deactivation
by antagonists. Receptors were inhibited by small interference RNA and the consequences in NM- and SP-induced
Camp (rCRAMP gene) expression and signal transduction were determined.
Results: We show an NM-induced increase of MARCO expression by immunofluorescence and real-time RT-PCR in
glial and meningeal cells. Receptor deactivation by antagonists and small interfering RNA (siRNA) verified the
importance of FPRL1 and MARCO for NM- and SP-induced Camp and interleukin-1b expression in glial cells.
Furthermore, we demonstrated a functional interaction between FPRL1 and MARCO in NM-induced signalling by
real-time RT-PCR, ERK1/2 phosphorylation and cAMP level measurement and show differences between NM- or SP-
induced signal transduction.
Conclusions: We propose that NM and SP induce glial cell activation and rCRAMP expression also via FPRL1 and
MARCO. Thus the receptors contribute an important part to the host defence against infection.
Background
Acute meningitis, caused by microorganisms such as bac-
teria, viruses, fungi and parasites, is a severe inflammatory
CNS disease. Bacterial meningitis alone accounts for
approximately 171,000 annual deaths worldwide (WHO
Health Report 2000). As the leading pathogens of bacterial
meningitis, Streptococcus pneumoniae and Neisseria
meningitidis comprise almost 80% of all cases [1]. Aside
from the blood-brain barrier, innate immunity forms the
first line of defence for pneumococci and meningococci
[2]. Host cells of the central nervous system, especially
microglia and astrocytes, release many factors, which help
to manage the infection and coordinate host defence cells
[3]. Amongst these factors are also antimicrobial peptides.
Antimicrobial peptides are effector molecules of the
innate immune system that have microbiocidal and
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proinflammatory properties [4,5]. Our previous results
show an increase of antimicrobial peptides (for example
human cathelicidin LL-37) in CSF of patients with bacter-
ial meningitis but not in control CSF [6]. Our results also
revealed increased expression of the rat cathelin-related
antimicrobial peptide (rCRAMP) by astrocytes and by
microglia as well as meningeal cells in vivo and in vitro
after bacterial stimulation [6,7]. Cathelicidins are defined
by a highly conserved N-terminal cathelin pro-domain
and a structurally variable antimicrobial domain at the C
terminus [8], and they have been identified in various spe-
cies. In rodents and humans one gene for cathelicidin is
known. This homolog gene encodes for the antimicrobial
peptide LL-37 in humans and CRAMP [9] and rCRAMP
[10] in mice and rats, respectively.
Recent studies suggest that the expression of antimi-
crobial peptides, like human beta defensine 2 (HBD-2)
is mediated through toll-like receptors 2 and 4 [11,12].
Furthermore it is indicated that the chemotactic G pro-
tein-coupled receptor formyl peptide receptor like-1
(FPRL1), expressed on both astrocytes and microglia, or
the scavenger receptor MARCO (macrophage receptor
with collagenous structure) play an essential role in the
inflammatory response of host defense mechanisms. It
has been shown that Neisseria meningitidis is a ligand of
and mediates host defence against infection through
MARCO [13,14]. Furthermore, MARCO is required for
lung defence against pneumococcal pneumonia [15]. In
addition a recent study showed an interaction between
FPRL1 and MARCO in Ab1-42-induced signal transduc-
tion in glial cells [16].
In this study we examined the time-dependent expres-
sion and co-localization of MARCO to glial cells in a
model of experimental pneumococcal and meningococ-
cal meningitis via fluorescence microscopy and using
real-time RT-PCR studies of primary rat glia cells. We
have been able to show a strong increase of MARCO in
meningococcal meningitis co-localized to astrocytes. We
investigated the function of FPRL1 and MARCO in the
signal transduction of Neisseria meningitidis (NM) and
Streptococcus pneumoniae (SP) by measuring extracellu-
lar-signal regulated kinase 1/2 (ERK 1/2) phosphoryla-
tion and cAMP levels in glial and transfected HEK cells.
Receptors were inhibited by small interfering RNA and
the consequences in NM- and SP-induced Camp (gene
name for rodent cathelicidin) or proinflammatory cyto-
kine interleukin 1b (IL-1b) expression and signal trans-
duction were determined. Our results demonstrate the
involvement of FPRL1 and MARCO in NM- and SP-
mediated signalling. The results suggest that FPRL1
plays a pivotal role in NM-induced signal transduction
in glial cells, and also show the capability of FPRL1 to
expand its inflammatory ligand spectrum by interaction
with the scavenger receptor MARCO.
Methods
Reagents
For the production of bacterial culture supernatants, bac-
teria were grown in stationary broth cultures for 20 h at
37°C until they had reached an optical density of 1.0. One
ml of this culture was added to 9 ml of fresh medium and
this was incubated for further 24 h in 75 cm2 flasks with-
out shaking. Brain heart infusion broth was used for the
cultivation of Streptococcus pneumoniae, and thioglycolate
broth supplemented with K1 and hemin was used for
Neisseria meningitidis. Broth cultures of the test bacteria
were centrifuged at 5000×g for 15 min, and the resulting
supernatants were filter-sterilized. The supernatants were
diluted 1:3 in EpiLife medium (Sigma, Germany) and used
for stimulation experiments. Growth medium (diluted
1:100 or 1:200) served as the negative control to evaluate
unspecific effects. Cells were challenged with supernatants
from Neisseria meningitidis (ATCC 13077, type strain iso-
lated from a fatal case of meningitis; 1:100) or Streptococ-
cus pneumoniae (ATCC 6303; capsula type 3; 1:100) in
serum and antibiotic-free DMEM.
FPRL1 antagonist WRW4 was purchased from Dr. P.
Henklein (Charité, Berlin, Germany). The peptide was
dissolved at 10 mM concentration in DMSO. Pertussin
toxin (PTX) and formyl-methionyl-leucyl-proline (fMLF)
were obtained from Sigma Chemical Company, Ger-
many. pERK and ERK2 antibodies were obtained from
Santa Cruz Biotechnology (CA, USA).
Cell Culture
Isolated cerebral cortices and rostral mesencephali from
2-day old rats were stripped of the meninges, minced
and dissociated enzymatically with trypsin from bovine
pancreas (Sigma) in phosphate-buffered saline and
50 μg/mL DNase I (Roche Molecular Biochemicals,
Indianapolis, IN, USA) for 30 min at 37°C and crushed
mechanically with Pasteur pipettes. Astrocytes were pre-
pared following the McCarthy and DeVellis method
[17], which allows for the preparation of nearly pure
cultures of astrocytes (> 97%) and cultivated in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS). Suspended microglial
cells were plated in 75 cm2 cell culture flasks in micro-
glial cell growth medium and harvested as described
[18]. Prior to replating microglial cells for different
assays, cell number and viability was estimated by trypan
blue exclusion. This procedure increased the purity of
the microglial preparation to > 98% with few astrocytes
remaining. To test cell purity, cultures were stained with
specific cell markers for astrocytes (glial fibrillary acidic
protein (GFAP); astrocytes marker; Sigma) and microglia
(OX42; microglia/macrophages marker; Sera-Lab, Lei-
cestershire, UK). The production of primary rat menin-
geal cells was described previously [7].
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HEK293 cells (American Type Culture Collection, Rock-
ville, MD, USA) were subcultivated in DMEM supplemen-
ted with 10% FCS and 1% penicillin/streptomycin (Carl
Roth, Karlsruhe, Germany). The transfection and selection
of HEK293 cells expressing hMARCO, hFPRL1 or coex-
pressing hFPRL1-hMARCO was described previously [16].
Astrocytes siRNA transfection
The astrocytes transfection was described previously [16].
Briefly, one day before transfection, 3 × 105/well astro-
cytes were seeded in DMEM containing 10% FCS in 6-
well-plates and transfected with Primefect® (Lonza, Riv-
erside, USA) transfecting agent containing control siRNA
(25 nM) and siRNA for target proteins (25 nM), respec-
tively according to the manufacturer’s recommendation.
Small interfering RNA (siRNA) duplexes corresponding
to rat FPRL1 and MARCO cDNA sequences (GenBank
accession number XM_001057934, XM_218012 and
XM_001054109) or control siRNA were purchased from
Qiagen, Valencia, CA, USA. Cells were cultured for an
additional 96 h and analyzed for mRNA expression via
SYBR green real time PCR.
RNA isolation and real time RT-PCR
Total RNA was isolated using the peqGold Trifast
reagent (peqlab, Erlangen, Germany) according to the
manufacturer’s protocol. RNA samples were reverse-
transcribed by moloney murine leukemia virus (MMLV)
reverse transcriptase (Fermentas, Burlington, Canada)
and random hexamer primers (Invitrogen, USA). The
cDNA products were used immediately for SYBR green
real-time RT-PCR for Camp (rat), FPRL1 as well as
MARCO and TaqMan real-time RT-PCR was used for
CAMP (gene name for human cathelicidin) and IL-1b.
Gene expression was monitored using the StepOne Plus
apparatus (Applied Biosystems, USA) according to stan-
dard protocol [19]. Relative quantification was per-
formed using the ΔCt method which results in ratios
between target genes and a housekeeping reference
genes (GAPDH or 18 s). The primer for Camp, FPRL1
and MARCO were manufactured by Qiagen (USA;
QuantiTect Primer Assay). The specificity of the ampli-
fication reaction was determined with a melting curve
analysis. We performed relative quantification of the sig-
nals normalizing the various gene signals with glyceri-
naldehyde-3-phosphate dehydrogenase (GAPDH) signal
(forward primer: TCTACCCACGGCAAGTTCAAC;
reverse primer: TCTCGCTCCTGGAAGATGGT; Euro-
fins MWG Operon, Germany) for SYBR Green real time
RT-PCR, and with 18 s for TaqMan real time PCR.
Western blotting
For western blot analysis of MAP kinases phosphoryla-
tion, glial or HEK293 cells were seeded in DMEM
containing 10% FCS. Cells were harvested in a lysis buf-
fer (50 mM Tris pH 7.5, 100 mM NaCl, 5 mM EDTA,
1% Triton, 2 mM sodium orthovanadate, 2.5 mM
sodium pyrophosphate, 1 mM glycerol 2-phosphate,
1 mM phenylmethylsulfonylfluoride). Proteins (5 μg for
pERK and ERK2) were resolved in SDS sample buffer,
and a western blotting procedure was performed as pre-
viously described in detail [20]. Membranes were incu-
bated with polyclonal primary antibodies against
pERK1/2 overnight at 4°C and subsequent detection was
performed with peroxidase-labeled secondary antibodies.
Antibody binding was detected via enhanced chemilumi-
nescence (Amersham Pharmacia Biotech, Essex, UK).
The membranes were then stripped and re-probed with
anti-ERK2 antibody as a loading control. The western
blot bands were densitometrically evaluated with the
program PC-BAS, the pERK-bands were adjusted with
their respective ERK-bands and subsequently, the values
were referred to control (= 100%).
Determination of receptor activity by measuring cyclic
AMP accumulation
1.5 · 105 astrocytes/well, or transfected HEK293 cells
or 5 · 105 microglia/well were seeded in 22-mm 12-well
dishes with DMEM containing 10% FCS and incubated
overnight. The medium was removed and replaced by
0.5 ml of serum-free DMEM medium containing 10 μM
forskolin (for astrocytes; Sigma) or 25 μM forskolin (for
microglia or HEK293 cells) plus agonists. Different for-
skolin concentrations were used because of different cell
sensitivities to forskolin-stimulated adenylate cyclase
activity. The cells were incubated at 37°C for 15 min,
and the reaction was terminated by removal of the cul-
ture medium and addition of 1 ml of ice-cold HCl/etha-
nol (1 N; 1 : 100, v/v). After centrifugation the
supernatant was evaporated, residues were dissolved in
Tris-EDTA (TE) buffer (50 mM Tris-EDTA, pH 7.5),
and cAMP content was determined using a commer-
cially available radioimmunoassay kit (Amersham Phar-
macia Biotech).
Infant rat model of experimental pneumococcal or
meningococcal meningitis
An established model of pneumococcal meningitis in
infant rats was used [21]. The animal studies were
approved by the Animal Care and Experimentation
Committee of the Canton of Bern, Switzerland. Wistar
rats were infected on postnatal day 11 by direct intracis-
ternal injection of 10 μl saline solution containing a
defined inoculum of Streptococcus pneumoniae (ser-
ogroup 3) or Neisseria meningitidis with a 32-gauge nee-
dle in the cisterna magna. The animals were sacrificed
at 12, 22 and 39 h for SP respectively 24 h for NM after
infection (n = 3/time intervall). Uninfected control
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animals were injected with 10 μl of a sterile saline solu-
tion. To document existence of bacterial meningitis,
CSF was obtained by puncturing the cisterna magna and
cultured quantitatively. Animals were sacrificed, and
perfused with 4% paraformaldehyde in PBS via the left
cardiac ventricle for immunohistological studies.
Fluorescence microscopy
Coronary brain sections (10 μm) from rats were cut on
a cryostat, collected on Superfrost Slides (Merck,
Braunschweig, Germany), air dried for 24 h and stored
at −80°C. For immunofluorescence staining, sections
were fixed with acetone (5 min), permeabilized with
0.1% Trition × in PBS for 10 min at room temperature,
incubated with rabbit anti-MARCO (1:100; sc-68913,
Santa Cruz, USA) and mouse anti-GFAP (astrocytes
marker; ab10062, Abcam, Cambridge, UK) overnight at
4°C. Finally, the slices were incubated with donkey anti-
rabbit AlexaFluor 488 (Molecular Probes, USA) or goat
anti mouse Cy3 (Sigma, Germany) for 1 h at room tem-
perature. Primary rat glial or different HEK293 cells
were grown on glass coverslips. Cells were then exposed
to NM or SP for 12 or 24 h at 37°C. After fixation with
ice cold methanol and acetone for 5 min and 20 sec-
onds, cells were blocked in 0.1 M Tris-HCl pH 7.5 con-
taining 1,5% bovine serum albumin (BSA; Sigma
Chemical Company, Germany) for 10 min. Coverlips
were incubated at 4°C overnight with primary antibodies
diluted in TRIS containing 1,5% BSA. The following pri-
mary antibodies were used for this study: rabbit anti-
MARCO antibody (1:100; Santa Cruz, USA), rabbit anti-
FPRL1 antibody (1:100; sc-18191, Santa Cruz, USA),
goat anti-rCRAMP antibody (1:100; sc-34170, Santa
Cruz, USA), and rabbit anti-LL-37 antibody (1:100;
ab64892, Abcam, Cambridge, UK). Finally, the coverlips
were incubated with donkey anti-rabbit AlexaFluor 488
or donkey anti-goat AlexaFluor 488 (all 1:250; Molecular
Probes, USA) for 1 h at room temperature. Nuclear
staining was performed with bisbenzimide (Sigma, Ger-
many). Cells were digitally photographed using a Zeiss
Axio Z1 Imager microscope (Zeiss, Göttingen,
Germany).
Statistical analysis
All experiments were performed at least in triplicate
and the values represent mean ± SEM. The significance
of the difference between test and control groups was
analyzed using the ANOVA test, followed by the Bon-
ferroni test. Data from the real-time RT-PCR, from den-
sitometric quantification of western Blots, and from
cAMP assay were analyzed using GraphPad Prism 5.0
software.
Results
Bacterial supernatants of Neisseria meningitidis induced
MARCO expression in primary rat astrocytes and
meningeal cells
In a first set of experiments we investigated the expres-
sion of both the FPRL1 and MARCO receptor by pri-
mary astrocytes, microglia and meningeal cells after
stimulation with either NM or SP bacterial supernatants
for 0, 6, 12, 24 h by real-time RT-PCR technique. As
shown in Figure 1A and 1C, NM or SP does not induce
a significant increase of FPRL1 expression in astrocytes
as well as microglia. Only in meningeal cells, SP induced
a significant increase of FPRL1 expression after 12 h
of treatment (4 ± 0.5-fold increase in expression;
Figure 1E). In astrocytes, a significant increase of
MARCO expression by NM after 12 h of treatment was
detected (5 ± 0.8-fold increase in expression; Figure 1B).
For SP treatment, we could not detect an increase of
MARCO expression. In microglia no significant changes
of receptor expressions were observed after NM as well
as SP treatment (Figure 1D). In meningeal cells, maxi-
mum MARCO expression was reached by NM after 24
h of treatment and by SP after 6 h of treatment (9 ±
0.6- and 6.1 ± 1.3-fold increase in expression, respec-
tively; Figure 1F).
We then examined the FPRL1 and MARCO expres-
sion in primary rat astrocytes and microglia cells after
treatment with NM and SP bacterial supernatants for
24 h using fluorescence microscopy. For FPRL1, both
primary cells showed a clearly protein expression, but
NM as well as SP could not induce an increased recep-
tor expression (Figure 2A). For MARCO, we could
detect an increase of protein expression in astrocytes
after NM treatment, whereas SP induced no change of
receptor expression in astrocytes as well as microglia
(Figure 2B).
Strong increased MARCO expression in astrocytes after
NM infection in an infant rat model of meningitis
In order to validate our previous in vitro findings in
vivo, we used double fluorescence microscopy with
receptor specific antibodies to examine the localization
of MARCO and GFAP in astrocytes from infant rats
with bacterial meningitis with NM or SP. Control rat
brains showed a very low positive GFAP staining, since
GFAP is a marker for activated astrocytes [22]. In corre-
spondence with real-time RT-PCR and immunofluores-
cence results, MARCO expression shows a strong
increase after 24 h of infection with NM as seen in
Figure 3A, with visible co-localization of MARCO and
GFAP in the sub-cortical area; Figure 3B. In addition
the meninges showed an increase of MARCO expression
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after NM infection. Positive MARCO staining and
MARCO/GFAP co-localization were also shown after
12, 22, 39 h of infection with SP, albeit weaker than in
meningitis by NM (Figure 3A). After SP infection an
increase of MARCO expression in meninges was also
detected. Interestingly we could show an increase of
MARCO expression after treatment with NM and SP in
meningeal cells. For FPRL1 however, only SP induced
increased expression (see Figure 1E and 1F).
Inhibition of NM- as well as SP-induced Camp (rat)
expression by FPRL1 antagonist WRW4 and G-protein
inhibitor pertussis toxin in glial cells
Our previous results show a physical and functional inter-
action between FPRL1 and MARCO [16]. Furthermore
we show an NM/SP-induced Camp (rat) expression in
glial cells with a maximum at 24 h for astrocytes respec-
tively 6 h for microglia [6]. Therefore, we investigated the
possible involvement of FPRL1 in NM/SP-induced Camp
expression in glial cells using real-time RT-PCR. As
shown in Figure 4A, astrocytes were incubated with NM
or SP with or without the FPRL1 antagonist WRW4 or
the G-protein inhibitor pertussis toxin (PTX) for 24 h and
Camp expression was determined. For microglia (Figure
4B), the cells were stimulated for 6 h. The results show
that WRW4 and PTX strongly decreased NM-induced
Camp expression (30.0 ± 8.8-fold increase) in astrocytes.
For SP treatment, we could not detect a change of Camp
expression after WRW4 or PTX co-stimulation, but also
SP alone did not significantly induce Camp expression.
Figure 1 Bacterial supernatants of Neisseria meningitidis induced MARCO expression in primary rat astrocytes and meningeal cells.
Astrocytes (A and B), microglia (C and D) and meningeal cells (E and F) were incubated with bacterial supernatants of Gram-positive bacteria
Streptococcus pneumoniae (SP) or Gram-negative bacteria Neisseria meningitidis (NM) for 0, 6, 12 and 24 h. FPRL1 or MARCO mRNA expression
was analyzed using SYBR green real-time RT-PCR and results were compared to the untreated sample. GAPDH (housekeeping gene) was used as
an internal control. The data were assessed from three independent experiments in triplicate. An asterisk indicates a significant difference (**, p <
0.001; *, p < 0.05) compared to control as determined by ANOVA followed by the Bonferroni test.
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Figure 2 Neisseria meningitides bacterial supernatants induced an increase of MARCO immunoreactivity in astrocytes. Primary rat
astrocytes and microglia were fixed and labelled with anti-FPRL1 and anti-MARCO antibodies. FPRL1 (A) and MARCO (B) protein expression was
examined by immunofluorescence microscopy. Bisbenzimide was used for nuclear counter-staining (blue). The figures show representative
results from one of three independent experiments. Scale bar: 20 μm.
Figure 3 Strongly increased MARCO expression in astrocytes after Neisseria meningitides infection in an infant rat model of
meningitis. Coronal brain sections from rats infected with Neisseria meningitidis (NM) or Streptococcus pneumoniae (SP) were fixed at defined
time-points after infection and immunolabeled using anti-MARCO (green) and anti-glial fibrillary acidic protein (anti-GFAP) antibodies to identify
astrocytes with nuclear counterstaining (blue). Sections were examined by double fluorescence microscopy. The figures show representative
results from one of three independent experiments. Scale bar = 200 μm for overview and 20 μm for the other images. (B) Shows a detail of (A).
Please note that the detail shows a strong colocalization between GFAP and MARCO in the sub-cortical layer after NM infection.
Braun et al. Journal of Neuroinflammation 2011, 8:11
http://www.jneuroinflammation.com/content/8/1/11
Page 6 of 15
In microglia, NM-induced Camp expression (11.7 ± 2.9-
fold increase) was inhibited by WRW4 or PTX
(Figure 4B). For SP treatment, WRW4 as well as PTX also
decreased Camp expression.
To confirm the real-time RT-PCR results, we examined
rCRAMP protein expression in primary rat astrocytes
and microglia cells after treatment with NM and SP with
different WRW4 concentrations using fluorescence
microscopy. For NM, bacterial supernatants induced
rCRAMP protein expression in glial cells after 24 h of
treatment in astrocytes and 12 h of treatment in micro-
glia (Figure 4C). NM-induced rCRAMP expression was
strongly decreased by 5 and 10 μM WRW4 in astrocytes
as well as microglia. Also, SP induced rCRAMP expres-
sion in astrocytes and microglia after 24 and 12 h of
treatment, respectively (Figure 4D). In astrocytes, only 10
Figure 4 Inhibition of Neisseria meningitidis as well as Streptococcus pneumoniae-induced Camp (rat) expression by the FPRL1
antagonist WRW4 and the G-protein inhibitor pertussis toxin in glial cells. Bacterial supernatants from Neisseria meningitidis (NM) or
Streptococcus pneumoniae (SP) were added to astrocytes (A) and microglia (B) with the addition of 200 ng/ml PTX (16 h preincubation) or 10
μM WRW4 (30 min preincubation) and with PTX (16 h preincubation) and WRW4 (30 min preincubation) alone to analyze the effect on Camp
mRNA expression after 24 h (astrocytes; a) or 6 h (microglia; b) of treatment. The induction was analyzed and compared to an untreated sample
(also with DMSO in equivalent amount). GAPDH (housekeeping gene) was used as an internal control. The data from three independent
experiments performed in triplicate were assessed. An asterisk (*, p < 0.05; **, p < 0.01) indicates a significant difference between Camp
expression after treatment and control (as determined by ANOVA followed by the Bonferroni test). Astrocytes or microglia were incubated with
NM (C) or SP (D) with or without 1, 5 or 10 μM WRW4 (30 min preincubation) and WRW4 alone for 24 h or 12 h, respectively. Glial cells were
fixed and labelled with anti-rCRAMP antibodies and protein expression was examined by immunofluorescence microscopy. Bisbenzimide was
used for nuclear counter-staining (blue). The figures show representative results from one of three independent experiments. Scale bar: 20 μm.
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μM WRW4 showed an inhibition of SP-induced
rCRAMP expression, whereas in microglia, 5 and 10 μM
WRW4 decreased SP-induced rCRAMP expression.
WRW4 alone could not induce rCRAMP expression in
astrocytes or in microglia.
Inhibition of NM- and SP-induced ERK1/2 phosphorylation
and change of cAMP levels by WRW4 and PTX in glial
cells
To investigate the effect of FPRL1 on NM- as well as
SP-induced glial cell activation we incubated primary
rat astrocytes and microglia with NM or SP to deter-
mine ERK1/2 phosphorylation and changes of cAMP
accumulation. As shown in Figure 5A to 5D, treatment
with NM as well as SP resulted in increased phosphory-
lation of ERK1/2 in both astrocytes (NM: 1.9 ± 0.2; SP:
1.6 ± 0.1) and microglia (NM: 2.0 ± 0.1; SP: 2.9 ± 0.1).
Therefore, as a next step, we tested the influence of
NM as well as SP on changes in cAMP levels in glial
cells. To determine whether NM and SP affected cAMP
formation via G-protein receptor activity, cAMP pro-
duction in glial cells was induced by forskolin treatment
(8.7 ± 1.6 pmol cAMP). Interestingly, NM (2.9 ±
0.3 pmol cAMP) as well as SP (3.0 ± 0.6 pmol cAMP)
induced a decrease in forskolin-induced cAMP accumu-
lation in glial cells (Figure 5E and 5F). Apparently their
activity is stimulated by an inhibiting G-protein. The
FPRL1 agonist fMLF (2.5 ± 0.9 pmol cAMP) was used
as a positive control. Next, we tested whether SP- or
NM-induced ERK1/2 phosphorylation and changes in
cAMP levels are mediated by inhibiting G-protein
coupled receptor FPRL1. We used the FPRL1 antagonist
WRW4 and pertussis toxin (PTX) as an inhibitor of
inhibitory G-proteins. We first investigated the inhibi-
tion of ERK1/2 phosphorylation by the antagonists. As
shown in Figure 5A and 5C, preincubation with WRW4
and PTX inhibited NM- as well as SP-induced ERK1/2
phosphorylation in astrocytes. In microglia, NM-induced
ERK1/2 phosphorylation was decreased using WRW4 or
PTX (Figure 5B and 5D). For SP, the induced ERK1/2
phosphorylation was inhibited by PTX, whereas WRW4
co-stimulation did not show a significant decrease. No
changes could be detected in ERK1/2 phosphorylation
with WRW4 and PTX alone. In addition to the assay
mentioned above, the effects of antagonists on NM- or
SP-induced cAMP formation was investigated. As
shown in Figure 5E and 5F, fMLF and NM-mediated
decreases in cAMP levels were inhibited by WRW4 in
both astrocytes and microglia. For SP, in astrocytes as
well as microglia, WRW4 had no effect on an SP-
induced decrease of cAMP level. WRW4 alone did not
alter forskolin-stimulated adenylate cyclase activity in
glial cells.
Inhibition of FPRL1 or MARCO expression in astrocytes by
siRNA results in a decrease of NM- as well as SP-induced
Camp as well as IL-1b expression and ERK1/2
phosphorylation
To determine whether FPRL1 as well as MARCO are
essential for NM- as well as SP-induced Camp as well
as cytokine expression and ERK1/2 phosphorylation, we
prepared siRNA targeting rat FPRL1 and MARCO in
astrocytes. Transfection of astrocytes with FPRL1 and
MARCO siRNA, but not with control siRNA, resulted
in a significant reduction in FPRL1 and MARCO mRNA
levels 96 h after transfection as determined by SYBR
green real time RT-PCR (Figure 6A and 6B). The trans-
fection of primary rat microglia did not reach sufficient
efficiency (data not shown). To investigate the effect of
FPRL1 and MARCO for NM- as well as SP-induced
Camp or IL-1b expression, astrocytes were transfected
with FPRL1 or MARCO siRNA as described above.
Ninety-six hours after transfection, Camp and IL-1b
expression was determined using real-time RT-PCR.
As shown in Figure 6C, treatment with NM as well as
SP for 24 h resulted in a strong increase of Camp
expression in astrocytes that had been transiently
transfected with control siRNA and also in untrans-
fected control cells. Transfection with FPRL1 but also
MARCO siRNA significantly inhibited NM- as well as
SP-induced Camp expression in astrocytes. Also the
NM- and SP-induced proinflammatory cytokine IL-1b
expression was significantly reduced by FPRL1 as well
as MARCO siRNA inhibition (Figure 6E). The receptor
activity was further determined by ERK1/2 phosphory-
lation. As shown in Figure 6D and 6F, treatment with
NM and SP resulted in an intense phosphorylation of
ERK1/2 in astrocytes that had been transiently trans-
fected with control siRNA and also in untransfected
control cells (about two- to threefold). Interestingly,
transfection with FPRL1 as well as MARCO siRNA
completely inhibited ERK1/2 phosphorylation induced
by NM and SP.
FPRL1 and MARCO mediate ERK1/2 phosphorylation and
changes of cAMP levels in transfected HEK293 cells
In an effort to further evaluate the effect of FPRL1 and
MARCO in NM/SP- and fMLF-induced signal transduc-
tion we used transfected HEK293 cells. Either hMARCO-
or hFPRL1-expressing, or hFPRL1 and hMARCO co-
expressing cells were generated and ERK 1/2 phosphory-
lation was analyzed after treatment with NM/SP and
fMLF for 5 and 15 minutes. The results of the western
blot were confirmed by densitometric quantification.
In untransfected cells no treatment led to an increase
in ERK 1/2 phosphorylation (Figure 7A and 7E).
In hMARCO-transfected cells, a 5-minute treatment with
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Figure 5 Inhibition of Neisseria meningitidis- and Streptococcus pneumoniae-induced ERK1/2 phosphorylation, and changes of cAMP
levels by WRW4 and PTX in glial cells. For analysis of ERK1/2 phosphorylation, astrocytes (A) and microglia (B) were each treated with
Neisseria meningitidis (NM) or Streptococcus pneumoniae (SP); with NM as well as SP for 5 min at 37°C with 200 ng/ml PTX (16 h preincubation)
or 10 μM WRW4 (30 min preincubation); they were also treated with PTX (16 h preincubation) or WRW4 (30 min preincubation) alone as control.
Cells were lysed, equal amounts of protein (5 μg) were dissolved in SDS sample buffer, and the levels of total ERK2 and phosphorylated ERK1/2
were determined via immunoblotting. The positions of phospho-ERK1/2 (pERK1/2) and total ERK2 (ERK2) along with those of the molecular mass
markers (in kDa) are indicated on the right or left side, respectively. The values representing mean ± standard error of the mean (SEM) of
phosphorylation levels derived from densitometric quantification of three independent experiments in astrocytes and microglia are indicated in
(C) and (D), respectively. An asterisk indicates a significant difference (*, p < 0.05; **, p < 0,01; ***, p < 0,001) compared to controls (also with
DMSO in equivalent amount) as determined by one-way ANOVA and Bonferroni post-hoc tests. In order to analyse the inhibition of forskolin-
stimulated adenylate cyclase activity, astrocytes (E) and microglia (F) were subjected to either 10 μM (E) or 25 μM (F) forskolin as well as to NM,
SP or 1 μM fMLF and NM, SP or fMLF with 10 μM WRW4 (30 min preincubation) and to WRW4 alone for 15 min at 37°C. cAMP levels were
determined as described above (see Methods). The values given represent mean ± SEM from four independent experiments. Asterisks indicate
significant differences (*, p < 0.05; ***, p < 0,001) between forskolin plus agonists and forskolin alone as determined by one-way ANOVA and
Bonferroni post-hoc tests.
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NM (6.5 ± 1.5 fold increase) and SP (11.3 ± 0.3 fold
increase) induced a significant increase in ERK1/2 phos-
phorylation (Figure 7B and 7F). As shown in Figure 7C
and 7G, hFRPL1-transfected cells also showed this
increase in phosphorylation, but here the treatment with
the FPRL1 agonist fMLF (6.6 ± 0.1 fold increase) also led
to increased phosphorylation after 5 minutes. Finally, in
hFPRL1 and hMARCO co-expressing cells a 5-minute
stimulation with all three substances significantly raised
the level of ERK phosphorylation (fMLF: 17.1 ± 1.1; NM:
19.7 ± 2; SP: 12 ± 1.8; Figure 7D and 7H). It should also
be mentioned that the increased phosphorylation after
fMLF and NM treatment in the co-expressing cells was
also significantly higher than that of cells transfected
with only one of the receptors. The above results are
reflected in a change in forskolin-induced adenylate
cyclase activity. In untransfected, or just hMARCO-
transfected, cells no change in cAMP concentration was
detected after treatment with fMLF and NM (Figure 7I
and 7J). In hFPRL1-transfected cells only the stimulation
with fMLF was able to reduce the cAMP level (2.6 ± 0.6
pmol; Figure 7K). Solely the FPRL1 and MARCO co-
expressing cells showed a decrease in adenylate cyclase
activity after treatment with either fMLF (4.3 ± 0.2 pmol)
or NM (2.6 ± 0.9 pmol; Figure 7L).
Increased CAMP/LL37 expression in transfected HEK293
cells
In an additional set of experiments we investigated the
effect of fMLF, NM and SP treatment for the human
cathelicidin CAMP (LL-37) in transfected HEK293 cells
mentioned above. After 0, 6, 12 or 24 h treatment with
fMLF, NM and SP CAMP expression as analyzed by
using real-time RT-PCR. As shown in Figure 8A to 8C,
Figure 6 Inhibition of FPRL1 or MARCO expression in astrocytes by siRNA resulted in a decrease of NM- as well as SP-induced Camp
as well as IL-1b expression and ERK1/2 phosphorylation. siRNA for FPRL1 and MARCO, as well as control siRNA, was transfected in
astrocytes and down-regulation of FPRL1 (A) and MARCO (B) mRNA expression was analyzed 96 h later using SYBR green real time RT-PCR and
compared to the untreated sample. GAPDH was used as an internal control (housekeeping gene). Data were assessed from three independent
experiments each performed in triplicate. Asterisks indicate a significant difference (*, p < 0.05) compared to control siRNA (one-way ANOVA
followed by the Bonferroni test). Transfected astrocytes were incubated 96 h, then incubated with SP or NM for 24 h and Camp (C) or IL-1b (E)
mRNA expression was determined using SYBR green or TaqMan real time RT-PCR and compared to the untreated sample. GAPDH or 18 s was
used as an internal control (housekeeping gene). Data were assessed from three independent experiments each performed in triplicate. Asterisks
indicate a significant difference (*, p < 0.05; **, p < 0.001) compared to NM or SP stimulated astrocytes transfected with control siRNA (one-way
ANOVA followed by the Bonferroni test). 96 h after transfection, (D) astrocytes were treated with NM or SP for 5 min at 37°C. Levels of total
ERK2 and phosphorylated ERK1/2 were determined using immunoblotting. The mean ± SEM of the three independent experiments was
evaluated by densitometric quantification (F). Asterisks indicate significant difference (*p < 0.05) compared to control (one-way ANOVA followed
by the Bonferroni test).
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Figure 8 Increased CAMP (human) expression in transfected HEK293 cells. For analysis of CAMP mRNA expression, untransfected (A) or
hMARCO- (B), hFPRL1- (C), and hFPRL1/hMARCO- (D) expressing HEK293 cells were treated with Neisseria meningitidis (NM), Streptococcus
pneumoniae (SP) or 1 μM fMLF for 0, 6, 12 and 24 h. mRNA expression was analyzed using TaqMan real-time RT-PCR and results were compared
to the untreated sample. 18 s (housekeeping gene) was used as an internal control. The data was assessed from three independent experiments.
Figure 7 FPRL1- and MARCO-mediated ERK1/2 phosphorylation and changes of cAMP levels in transfected HEK293 cells. For analysis of
ERK1/2 phosphorylation, untransfected (A) or hMARCO- (B), hFPRL1- (C), and hFPRL1/hMARCO- (D) expressing HEK293 cells were treated with
Neisseria meningitidis (NM), Streptococcus pneumoniae (SP) or 1 μM fMLF for 5 and 15 min at 37°C. Cells were lysed, equal amounts of protein (5
μg) were dissolved by SDS sample buffer, and levels of total ERK2 and phosphorylated ERK1/2 were determined via immunoblotting. The
positions of molecular mass markers are indicated on the left (in kDa). The mean ± SD of the three independent experiments were evaluated by
densitometric quantification normalized to ERK2 expression (E to H). Asterisks indicate a significant difference (*, p < 0.05; **, p < 0,01; ***, p <
0,001) compared to control (one-way ANOVA followed by the Bonferroni test). For analysis of inhibition of forskolin-stimulated adenylate cyclase
activity, untransfected (I) or hMARCO- (J), hFPRL1- (K), and hFPRL1/hMARCO- (L) expressing HEK293 cells were subjected to 25 μM forskolin as
well as to NM or 1 μM fMLF for 15 min at 37°C. cAMP levels were determined as described above (see Methods). The values represent mean ±
SEM from four independent experiments. Asterisks indicate a significant difference (*, p < 0.05; **, p < 0,01) between forskolin plus agonists and
forskolin alone, as determined via one-way ANOVA followed by the Bonferroni test.
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in untransfected and cells transfected only, with either
hFPRL1 or hMARCO, stimulation with either substance
did not change the expression of CAMP mRNA. Only
in hFPRL1 and hMARCO co-transfected cells (Figure
8D) did the treatment with fMLF show a maximum
increase of CAMP mRNA expression after 6 h (4-fold
increase). NM induced a maximum induction of CAMP
expression at 24 h of treatment (3.9-fold increase). SP
did not alter CAMP expression in hFPRL1-hMARCO-
expressing HEK293 cells.
To confirm the real-time RT-PCR results, we exam-
ined LL-37 protein expression in transfected HEK293
cells after treatment with NM, SP and fMLF for 24 h
using fluorescence microscopy. As shown in Figure 9 in
untransfected and in HEK293 cells transfected only with
hMARCO, stimulation with either substance did not
change the expression of LL-37 protein. In hFPRL1-
transfected cells, fMLF induced a strong, and NM a
weak, LL-37 protein expression, whereas in hFPRL1 and
hMARCO co-transfected cells treatment with NM and
fMLF showed a clear increase of LL-37 expression.
Discussion
Our present study shows a functional influence of the
FPRL1 and MARCO receptors in NM- and SP-induced
signal transduction and expression of the antimicrobial
peptide rCRAMP in glial cells. In previous investigations
we were able to show an increased expression of LL-37/
rCRAMP in bacterial meningitis localized to astrocytes
and microglia [6], as well as a functional interaction
between the FPRL1 and MARCO receptors in neurode-
generative disease signalling [16]. Now, we demonstrate
differences between NM- and SP-induced glial cell acti-
vation. The activation of different signal transduction
pathways (ERK1/2 and cAMP level measurement) and
increased Camp (rat) and proinflammatory cytokine IL-
1b expression in primary rat glia cells by NM and SP is
dependent on the FPRL1 and MARCO receptor, as veri-
fied by antagonist treatment, receptor inhibition by
siRNA and using transfected HEK293 cells.
Using an infant rat model of experimental pneumo-
coccal and meningococcal meningitis and a primary glia
cell culture, our results show a strong increase of
Figure 9 Increased LL-37 protein expression in transfected HEK293 cells. Untransfected or hFPRL1-, hMARCO- or hFPRL1/hMARCO-
expressing HEK293 cells were incubated with NM or SP for 24 h. Cells were fixed and labelled with anti-LL-37 antibodies and protein expression
was examined by immunofluorescence microscopy. Bisbenzimide was used for nuclear counter-staining (blue). The figures show representative
results from one of three independent experiments. Scale bar: 20 μm.
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MARCO expression after NM infection in astrocytes but
not in microglia. FPRL1 expression in astrocytes as well
as microglia was not changed (Figure 1 and 2), whereas
SP induced an increase of FPRL1 expression in menin-
geal cells. MARCO expression in meningeal cells was
increased by NM as well as by SP (Figure 1). For glial
cells, we have previously been able to show a basal
FPRL1 expression in astrocytes and an even stronger
one in microglia [20]. For MARCO expression, Alarcon
et al. [23] could show an equally strong endogen expres-
sion in astrocytes as well as microglia. As shown by
Mukhopadhyay et al. [14] and Plüddemann et al. [24]
NM is an important ligand for MARCO. MARCO is
involved in defence against pneumococcal pneumonia
[15]. This receptor mediates immunological responses in
combination with other receptors, like Toll-like recep-
tors and other scavenger receptors on macrophages.
The glial cell reactions thus depend on the kind of the
bacterium and on the expressed receptor pattern. How-
ever, in astrocytes, challenge with NM significantly
increased MARCO expression, thus enhancing these
cells’ ability to react to and defend against Neisseria
infection. Possibly, meningeal cells act as antigen-pre-
senting cells in this compartment for glial or invading
immune cells [25].
Differences between astrocytes and microglia also
showed up regarding the NM/SP-induced signal trans-
duction in glial cells (Figure 5). NM-induced ERK1/2
phosphorylation and changes of cAMP level were clearly
inhibited by the FPRL1 antagonist WRW4, whereas for
SP, the induced signal transduction was not decreased
by WRW4. This is possibly based on differences
between formyl peptides from Gram-positive and/or
Gram-negative bacteria. In Gram-negative bacteria
Escherichia coli culture supernatants, the chemotactic
peptide fMLF is a major chemoattractant [26]. On the
other hand, different receptors possibly play a more
important role in SP-induced signal transduction in glial
cells. It has been shown that pneumococcal infection of
the central nervous system (CNS) depends on TLR2 and
TLR4 [27]. In addition, an involvement of the pattern
recognition receptor nucleotide-binding oligomerization
domain-2 (NOD2) in the inflammatory response of
murine glia to SP could be shown [28]. Furthermore,
our results show that SP-induced ERK1/2 phosphoryla-
tion in microglia is PTX-sensitive. For ERK1/2 phos-
phorylation and changes of cAMP levels in glial cells,
thus, at least one unknown G-protein coupled receptor
seems to be involved (Figure 5). However, transfection
of astrocytes with FPRL1 as well as MARCO siRNA
reduced NM- and SP-induced ERK1/2 phosphorlylation
(Figure 6). The results with transfected HEK293 cells
show that in cells only transfected with hFPRL1 or
hMARCO, SP and NM induce ERK1/2 phosphorylation
(Figure 5). Interestingly, in HEK293 cells co-transfected
with hFPRL1 and hMARCO, ERK1/2 phosphorylation
was stronger than in other transfected cells after NM or
SP treatment. Taken together, the data suggest a colla-
boration between FPRL1 and MARCO triggering cellu-
lar responses after NM or SP infection. While the
change of cAMP level after NM treatment is possibly
mediated by FPRL1, both receptors are involved in NM-
and SP-induced ERK1/2 phosphorylation and have
synergistic effects for ERK1/2 phosphorylation after NM
or SP treatment.
In addition, the increased Camp expression by NM in
the glial cells seems to be mediated generally by FPRL1
(Figure 4). However, binding of MARCO is needed
because, considering our results with siRNA and in
HEK293 cells, CAMP/LL-37 expression is linked to the
presence of FPRL1 and MARCO (Figure 6 and 8). The
involvement of a different receptor spectrum in SP-
induced Camp expression can be assumed even more,
considering the CAMP expression in transfected
HEK293 cells. Here SP was not able to show any effect
with only the FPRL1 and MARCO receptors present
(Figure 8 and 9); but in astrocytes FPRL1 and MARCO
siRNA reduced SP-induced Camp expression (Figure 6).
Possible other receptor candidates in NM and SP signal-
ling and Camp induction TLRs have to be mentioned
[29]. This difference in expression could also explain the
observed Camp expression in glia cells. CRAMP expres-
sion is most likely an important part of the glial cell-
mediated immune response in bacterial meningitis.
CRAMP KO mice show a clearly higher susceptibility
for meningococcal infection than do WT mice [30].
Cruse et al. could show that human lung mast cell-
released LL-37 is antimicrobial against SP [31]. Our pre-
vious studies demonstrate cytokine releasing and antimi-
crobial effects of rCRAMP/LL-37 in a meningitis setting
[7]. In addition our results have demonstrated an
rCRAMP-mediated glial cell activation, which accompa-
nies an increase of neurotrophic factor expression by
glial cells, so rCRAMP, apart from the immune response
in the CNS, is also involved in neuroprotection [32].
Further investigations should clarify to what extent dif-
ferences exist between the various meningitis strains.
These findings could also offer an explanation for clini-
cal differences concerning neurological sequelae of NM
and SP [33,34].
In conclusion, our results show the importance of the
FPRL1 and MARCO receptors in host defence against
NM and SP, and show a cooperative signal transduc-
tion-enhancing effect of the MARCO receptor. Our
results document important differences between the
meningitis-causing bacterial pathogens NM and SP
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regarding glial cell activation. Future investigations
could help develop more specific approaches against
infections of the CNS.
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